Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
  • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
  • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D309/30—Oxygen atoms, e.g. delta-lactones
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

• the invention belongs to the field of organic chemistry and relates to a process for the preparation of the HMG-CoA- reductase inhibitor simvastatin and derivatives thereof.
• Simvastatin is a semi-synthetic analog of the natural fermentation product lovastatin which has a 2-methylbutyrate side chain in the 8-position of the hexahydronaphthalene ring system. It has been discovered that the replacing of the 2- methylbutyrate group by a 2, 2-dimethylbutyrate group results in more active inhibitors of HMG-CoA reductase (J. Med. Chem., 1986, 29(5) , 849-852) .
• the known processes for preparing simvastatin and derivatives thereof can basically divided according to two synthesis approaches used, namely (A) the so-called re-esterification route and (B) the direct methylation of the methyl butyrate side - 2 - chain .
• the re- acylation (4) is carried out at a high temperature of 100°C for prolonged time (18-36 hours) m the presence of 4-pyrrol ⁇ dmo pyridme or dialkylammo py ⁇ dme.
• These reaction conditions lead to formation of a substantial amount of undesired byproduct (unsaturated lactone) resulting from the elimination of the tert .-butyldimethylsilyloxy radical, present as protecting group of the alcohol, from the ⁇ -valerolactone moiety.
• undesired byproduct unsaturated lactone
• tert .-butyldimethylsilyloxy radical present as protecting group of the alcohol
• also large amounts of starting diol lactone and unconsumed acid chloride remain at the end of the reaction.
• an improved acylation process for the preparation of antihypercholesterolemic compounds which comprises the combining of a suitable acid chloride with an alkali metal bromide, dialkylaminopyridme and a polyhydro- naphthyl alcohol to obtain the corresponding acylated product.
• the reaction is carried out at a relatively high temperature of 70 C so the unsaturated lactone by-product is also formed m an amount of about 1-2%.
• the preferred solvent used m this process is pyridme which is environment and people unfriendly.
• the second synthesis approach the direct alkylation of the methyl butyrate side chain, is disclosed m EP-B-137 445 and EP- B-299 656.
• the processes involve use of a metal alkyl amide and methyl halide.
• the mam disadvantage of these processes is the contamination of the product by a significant amount of unconverted starting materials, e.g. lovastatm. Since simvastatin and lovastatm differ only by one methyl group, it - 3 - is very difficult to isolate by means of conventional separation methods simvastatin from a mixture containing both. Thus, an additional purification step is normally required, for example the selective hydrolysis of residual lovastatin as per the method disclosed in WO 93/16188.
• N-methylimidazole also referred to as 1-methylimidazole
• 1-methylimidazole is a known compound useful for the acetylation of hydroxy compounds with acetic anhydride (see Anal. Chem. 5_0, 1542-1545 (1978)).
• the reaction with sterically hindered alcohols gives only a poor yield. In case of tert. -butyl alcohol the yield is only 36%.
• N- methylimidazole can also be employed as a catalyst for the acetylation of hydoxyl-terminated polymers by acetic anhydride.
• - R is a Ci to C ! alkyl group and - Ri is a protecting group or H
• process comprises - 4 -
• steps (a) and/or (b) are carried out in the presence of N-methylimidazole .
• the compounds of formula (I) are effective antihyper- cholesterolemic compounds and include in particular simvastatin.
• the group R can be a Ci to d t branched or straight alkyl group or a C to C : cyclic alkyl group, - 5 - preferably a C 5 alkyl group and in particular CH 3 -CH-C (CH 3 ) 2 - .
• Suitable examples of protecting groups Ri are groups conventionally used for selectively protecting hydroxy groups, such as silyl groups.
• Preferred are trialkyl silyl groups, such as isopropyldimethylsilyl, (triphenylmethyl) dimethylsilyl, tert.- butyldiphenylsilyl, methyldiisopropylsilyl, tribenzylsilyl, triisopropylsilyl and a particularly preferred example is the tert .-butyldimethysilyl group.
• the compounds (I) can be prepared by the acylation process according to the invention in a very efficient manner and with high yield without formation of substantial amounts of undesired by-product. It was found out that particularly good results are obtained if N-methylimidazole is present in both process step (a) and (b) . Thus, N- methylimidazole seems to act as a catalyst not only for the protection step (a) but also for the acylation step (b) resulting in an excellent overall yield.
• the diol lactone (II) used in step (a) is for example available by hydrolysation of lovastatin according to the method disclosed in EP-B-33 538.
• step (a) In case of the introducing of a silyl group, such as the tert.- butyldimethyl silyl group, as a protecting group, the yield obtained in step (a) is virtually 100%. As practically no byproducts are formed in step (a) , it is possible to carry step (a) and (b) out as a one-pot reaction without the need to isolate the formed protected diol lactone (Ila). This preferred embodiment of the invention greatly simplifies the preparation of the desired compound (I) . It was also found out that due to the presence of N-methylimidazole the reaction time for completing (a) is decreased and is normally only 1.5 to 4 h.
• the N-methylimidazole is preferably used in an amount sufficient to dissolve at the chosen reaction temperature the diol lactone - 6 -
• step (II) and (Ila), respectively can also serve as a solvent. Due to the possibility of employing it in step (a) and (b) there is no necessity to change the solvent after completion of step (a) which is very advantageous when carrying out a one-pot synthesis.
• the steps (a) and/or (b) can be carried out at low temperatures and in particular in the range of about 0 to about 30 C.
• the low reaction temperature especially when conducting the acylation reaction (b) results in a substantially reduction of the level of by-products, such as unsaturated lactone by-product.
• the acylation step requires temperatures of 100°C or 70°C.
• the acylating step (b) is preferably carried out by reacting the protected diol lactone (Ila) with a suitable activated form of the acid of formula (III)
• Preferred activated forms are the corresponding acid anhydrides or acid halogenides .
• Particularly suitable are acid chlorides.
• the acid halogenides or acid anhydrides are commercially available compounds or can be prepared from known starting materials utilising standard chemical transformations.
• the protecting - 7 - group Ri is removed by conventional means to give the corresponding compound of formula (I) where R. is H, such as simvastatin.
• R. is H
• silyl protecting groups can be split off by using tetrabutylammonium fluoride/ acetic acid and a corresponding procedure is described in EP-B-33 538, or by using boron trifluo ⁇ de etherate as is disclosed EP-A-444 888.
• lovastatin used in this sequence as starting material is commercially available or can be prepared by known processes, e.g. those described in EP-B-22 478 or WO 97/05269.
• lovastatin is hydrolysed under the conditions disclosed in EP-B-33 538 to give the diol lactone (II) .
• the silyl protecting group and acylation in the presence of N- methylimidazole the corresponding compound (I) is formed. This can optionally be converted in the deprotected compound (I) where Ri is H by treatment with tetrabutylammonium fluoride/ acetic acid in tetrahydrofuran.
• the invention is in the following illustrated by examples.
• content determination is performed by a HPLC analysis .
• the purity of the product determined by HPLC was 97-98.5 area %.
• the level of unsaturated by-product was under 0.5%.
• the content of the product was 93%.
• the formed compound can be converted into simvastatin by removing the silyl protecting group in a conventional manner.
• Lithium bromide (2,08g, 12 mmol, anhydrous, dried 4 days at 135°C in vacuum) was added as rapidly as possible to a solution of 2,2-dimethylbutyryl chloride (1,62 ml, 12 mmol) in anhydrous pyridine (7 ml) under N 2 .

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pyrane Compounds (AREA)
• Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (14)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=20432210

Family Applications (1)

Country Status (18)

Cited By (2)

Families Citing this family (10)

Citations (3)

Family Cites Families (6)

• 1998
  • 1998-02-26 SI SI9800057A patent/SI9800057A/sl unknown
• 1999
  • 1999-02-24 UA UA2000095504A patent/UA56303C2/uk unknown
  • 1999-02-24 PL PL99342511A patent/PL194713B1/pl unknown
  • 1999-02-24 SK SK1258-2000A patent/SK284137B6/sk not_active IP Right Cessation
  • 1999-02-24 HU HU0100743A patent/HU227916B1/hu not_active IP Right Cessation
  • 1999-02-24 DE DE69908909T patent/DE69908909T2/de not_active Expired - Lifetime
  • 1999-02-24 EA EA200000881A patent/EA002370B1/ru not_active IP Right Cessation
  • 1999-02-24 WO PCT/SI1999/000006 patent/WO1999043665A1/en active IP Right Grant
  • 1999-02-24 CZ CZ20002857A patent/CZ297405B6/cs not_active IP Right Cessation
  • 1999-02-24 EE EEP200000479A patent/EE04345B1/et not_active IP Right Cessation
  • 1999-02-24 AU AU32846/99A patent/AU3284699A/en not_active Abandoned
  • 1999-02-24 EP EP99936072A patent/EP1056737B1/en not_active Expired - Lifetime
  • 1999-02-24 AT AT99936072T patent/ATE243207T1/de not_active IP Right Cessation
  • 1999-02-24 RS YUP-466/00A patent/RS49712B/sr unknown
• 2000
  • 2000-07-07 HR HR20000467A patent/HRP20000467B1/xx not_active IP Right Cessation
  • 2000-08-23 NO NO20004221A patent/NO326301B1/no not_active IP Right Cessation
  • 2000-09-05 BG BG104749A patent/BG64826B1/bg unknown
  • 2000-09-22 US US09/668,101 patent/US6252091B1/en not_active Expired - Fee Related

Patent Citations (3)

Also Published As

Similar Documents

Legal Events